Corcept Therapeutics (CORT) Director Wilson Sells $1.1M of Stock

Corcept Therapeutics Incorporated director James N Wilson sold 10,000 shares of the biotechnology firm on October 15, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the transaction was executed at a price of $114.81 per share, totaling roughly $1.15 million. This sale was carried out under a pre-arranged trading plan.

Inside James N Wilson's Corcept Trade

For Wilson, this sale represented a notable reduction in his holdings. The shares were traded on a day when Corcept stock closed at $113.37. The transaction falls under a planned trading arrangement designed to let insiders buy or sell company stock according to a set schedule without running afoul of insider trading rules.

Other Institutional Activity in Corcept Therapeutics

Other large institutional investors have also adjusted their positions in the drug developer recently. Ingalls & Snyder LLC grew its holdings by 325,659 shares in the second quarter, ending with 7,934,507 shares valued at $874.07 million. Renaissance Technologies, LLC reduced its stake by 421,089 shares to finish the period with 5,261,628 shares worth $579.62 million. Parallel Advisors, LLC trimmed its position by 15,114 shares, leaving it with 3,962,177 shares valued at $436.47 million. Meanwhile, AQR Capital Management, LLC significantly expanded its exposure by adding 2,176,357 shares for a total of 2,582,561 shares worth $284.49 million, representing a 535.8% increase for the fund. Caption Management also established a new position earlier in the year by buying 260,000 shares.

Corcept Therapeutics Incorporated Stock Down 3.7%

Corcept shares recently traded around $109.19, down about 3.7% from the event-day close and roughly 13.6% below its 52-week high of $126.38. Even so, the stock remains up substantially over the longer term, trading 52.6% above its 200-day moving average of $71.56.

Recent Earnings

The company reported trailing twelve-month revenue of $830.81 million and earnings of $0.45 per share. Its next financial update is scheduled for November 4, 2026.

Insider Buying and Selling at Corcept Therapeutics Incorporated

Insiders have been active sellers as the share price has climbed. Wilson previously sold 10,000 shares on September 15, 2026, for about $1.11 million. Other recent transactions include officer Roberto W Vieira selling 8,333 shares on October 2, 2026, for roughly $967,448, officer Sean Maduck selling 25,000 shares on the same day for about $2.91 million, and chief technology officer Joseph Douglas Lyon selling 10,000 shares also on October 2 for roughly $1.16 million.

Analysts Set New Price Targets

Wall Street analysts maintain a generally positive view of the company. Canaccord Genuity, Piper Sandler, and HC Wainwright & Co. have issued various buy and overweight ratings through the summer and autumn, with price targets ranging up to $165.00.

About Corcept Therapeutics

Corcept Therapeutics is a Redwood City, California-based biopharmaceutical company that focuses on discovering and developing treatments for severe endocrinologic, oncologic, metabolic, and neurologic disorders.

Bottom Line

Investors will look toward the upcoming November earnings report for fresh details on the company's financial trajectory. Insider sales under planned schedules continue to draw attention as the stock holds strong gains above its long-term moving averages.